C.V. Herst received his undergraduate degree in Bacteriology and his master’s degree in Public Health from U.C. Berkeley, after which he was hired by Cetus Corporation, one of the original biotechnology companies, where he was on the cloning teams for IFN-beta, IL-2, and TNF-alpha. In 1989 he earned his Ph.D. in Tumor Cell Biology from Northwestern University. In his post-doctoral fellowship at MD Anderson Cancer Center, he researched bcr-abl breakpoint variations in chronic myelogenous leukemia. His career research efforts have led to approved therapies for systemic fungal infections, Multiple Sclerosis, certain cancers, as well as FDA approvals for medical devices. He has been a member of the Flow Pharma team since 2004.